The business model of Camurus AB is focused on the development and commercialization of innovative pharmaceutical products. Camurus specializes in long-acting medications, utilizing their proprietary FluidCrystal® technology to create advanced drug delivery systems. These systems enhance the efficacy, safety, and convenience of medication administration. The company primarily operates in the field of severe and chronic conditions, particularly within pain management and addiction treatment. By leveraging their expertise in drug formulation and delivery, Camurus aims to improve patient outcomes and quality of life.

Camurus AB is primarily active in the pharmaceutical industry.

The main competitors of Camurus AB in the market are pharmaceutical companies such as Indivior PLC, Titan Pharmaceuticals Inc., and DURECT Corporation.

Camurus AB is a Swedish pharmaceutical company specializing in developing and commercializing innovative drug delivery systems. Founded in 1991, Camurus has built a strong reputation for its proprietary drug delivery technologies, including the FluidCrystal® and the Buvidal® depot products. The company has successfully delivered numerous products to market, primarily in the areas of pain management and opioid dependence. With a focus on providing effective and patient-friendly medications, Camurus AB continues to expand its product portfolio and collaborate with global partners. This steadfast commitment to innovation has established Camurus AB as a leader in the pharmaceutical industry.

Some significant milestones achieved by Camurus AB include the approval and launch of their opioid dependence treatment medication, Buvidal® (buprenorphine and naloxone extended-release solution), in several countries, including the United States and European Union. The company has also received regulatory approvals for their product pipeline, such as the long-acting CAM2038 for the treatment of opioid addiction and pain, which further strengthens their position in the pharmaceutical market. Additionally, Camurus AB has formed strategic partnerships and collaborations with various pharmaceutical companies to commercialize their products globally. These milestones highlight the company's commitment to innovation and healthcare advancements in the treatment of addiction and pain management.

Camurus AB is primarily present in several countries and regions. The company has a strong presence in Europe, with a focus on Scandinavia. It operates in Sweden, where it is headquartered, as well as in Norway, Denmark, and Finland. Additionally, Camurus AB has expanded its operations to other European countries, including the United Kingdom, Germany, France, and Spain. It aims to further expand its global footprint through strategic partnerships and collaborations.

Analysts currently set an average price target of 790,50 SEK for the Camurus stock (median: 795,60 SEK), implying +31,2 % versus the latest price. The consensus is based on 15 analyst ratings.

Camurus Analyytikkojen kursstavoitteet 2026

15 analysts currently rate the Camurus stock: 13 recommend buying, 2 holding and 0 selling. For 2026, analysts expect Camurus to generate revenue of 2,82 Mrd. SEK and earnings per share of 14,94 SEK.

Camurus Analyytikkojen kursstavoitteet 2026

Converted at the current exchange rate, the Camurus share trades at 56,24 EUR (617,50 SEK).

The Camurus share (CAMX.ST) is listed on 7 stock exchanges, including: Frankfurt (7CA.F), Düsseldorf (7CA.DU), London (0RD1.L), London (0RD1.L).

Camurus AB is a Swedish biopharmaceutical company specializing in the development of innovative drugs. The company was founded in 1991 and is headquartered in Lund. Camurus has unique expertise in the formulation and manufacturing of long-acting drugs and is a leader in the development and commercialization of products for pain treatment, addiction disorders, and oncology. Camurus employs over 200 employees worldwide and pursues an international growth strategy with a focus on North America and Europe. The company collaborates closely with research-based pharmaceutical companies and academic institutions to help innovative drugs break through. Camurus is a strong and strategically focused company with a high degree of flexibility, dynamism, and innovation spirit. Camurus has two main divisions: the "Pharmaceuticals" business unit and the "Biovive" business unit. The "Pharmaceuticals" business unit focuses on the discovery and development of long-acting drugs in various therapeutic areas such as pain, addiction disorders, and oncology. The "Biovive" business unit is dedicated to the development of clinical dietary supplements and diagnostics to support oncology patient care. Camurus' flagship product is the opioid substitution preparation "Bunavail," which is used to treat opioid dependency. The uniqueness of Bunavail is that it is applied as a film on the inner cheek, ensuring a slow and continuous release of the active ingredient. This achieves better therapeutic effectiveness while reducing the potential for abuse. Camurus has other products in the pipeline, such as the pain product "CAM2038," which is intended for long-term therapy in chronic and acute pain. Camurus has successfully partnered with major pharmaceutical companies such as Braeburn Pharmaceuticals, ICM Pharma, and Meda to distribute its products worldwide. Camurus is also able to market its own products that are registered in the US, Europe, and other key markets. The company has international offices in the US and Europe and is continuously working to expand its network to increase global presence and growth. In summary, Camurus is an innovative biopharmaceutical company that focuses on the development of long-acting drugs in various therapeutic areas. Camurus' unique technology provides patients with better therapeutic effectiveness and safe drug handling, contributing to a better quality of life for patients. Camurus has a clear growth strategy to strengthen its position as a leading provider in the industry.

odotettu liikevaihto Camurus on 2,82 Mrd. SEK. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.

odotettu voitto Camurus on 901,25 M SEK. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.

Camurus:n hinta-voitto-suhde (P/E) on tällä hetkellä 41,32. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Camurus-osakkeen arvostusta.

Camurus:n hinta-myynti-suhde (P/S) on tällä hetkellä 13,21. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Camurus-osakkeen arvostuskennuslukuna.

Camurus:n Eulpool-laatuscore on 7/10.

Camurus:n ISIN on SE0007692850. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.

Camurus:n WKN on A2ABG7. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.

Camurus:n ticker on CAMX.ST. Tämä pörssinoteeraus käytetään Camurus-osakkeiden kauppaan pörssissä.

Camurus maksoi osinkoa joka vuosi viimeisten 0 vuoden aikana.

Camurus kuuluu sektoriin 'Terveydenhuolto'.

Camurus:n osingot jaetaan valuutassa SEK.